Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2019

Shelley Wood

December 31, 2019

News Daily News

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Todd Neale

December 23, 2019

News Daily News

Poor Exercise Capacity on Stress Echo in Women Predicts Death From CVD

Michael O'Riordan

December 10, 2019

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Daily News

Morphine Not Linked to Increased Short-term Mortality in STEMI: Meta-analysis

L.A. McKeown

November 01, 2019

Presentation

Identification of Patients at Higher Risk for Myocardial Injury Following Elective PCI

October 29, 2019

News Daily News

Elderly Women Worse Off Than Men Before and After Acute MI

Yael L. Maxwell

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2019

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Poor Exercise Capacity on Stress Echo in Women Predicts Death From CVD

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

No Benefit of Colchicine in All-Comers PCI

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Morphine Not Linked to Increased Short-term Mortality in STEMI: Meta-analysis

Identification of Patients at Higher Risk for Myocardial Injury Following Elective PCI

Elderly Women Worse Off Than Men Before and After Acute MI

Recurrent Events Common Among Young Patients With CAD

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content